8-K current report · filed Oct 19, 2026

EyePoint, Inc. (EYPT) 8-K Current Report: October 19, 2026

Item 2.02Item 2.05Item 8.01Item EX-99.1EYPT overview

Short answer

EyePoint, Inc. (EYPT) filed an 8-K current report with the SEC on October 19, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 2.05 (Costs Associated with Exit or Disposal Activities), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Preliminary cash, cash equivalents and short-term investments reported as of September 30, 2026.

EyePoint, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Preliminary cash, cash equivalents and short-term investments reported as of September 30, 2026
  • Liquidity figures remain unaudited and may change after quarter-end financial statement completion
  • Investors should review the accompanying press release for the disclosed liquidity amount

Item 2.05 · Costs Associated with Exit or Disposal Activities

  • Wet AMD Phase 3 trials to end early after LUCIA topline review, signaling reduced development prospects for DURAVYU in wet AMD
  • Resources redirected to late-stage DME trials, COMO and CAPRI
  • Workforce reduction approximately 53%, mainly during Q4 2026 and completed by first half of 2027
  • Estimated restructuring charges approximately $9 million, primarily recognized in Q4 2026 and paid through Q3 2027
  • Cash runway may benefit from lower operating expenses, but execution and additional-cost risks remain significant

Item 8.01 · Other Events

  • EyePoint announced a “Prioritization” initiative, signaling a potential shift in strategic or capital-allocation focus
  • Investor impact depends on Exhibit 99.1, which contains the underlying details and expected business implications

Item EX-99.1 · Exhibit EX-99.1

  • LUCIA Phase 3 wet AMD trial missed non-inferiority primary endpoint, ending EyePoint’s lead indication path
  • Wet AMD pivotal trials to stop early, reducing development value but limiting further trial spending
  • Workforce reduction of approximately 53%, with approximately $30 million annualized savings and approximately $9 million one-time charges
  • Cash, cash equivalents and short-term investments totaled approximately $118 million as of September 30, 2026
  • Capital redirected to DME Phase 3 trials, with 551 patients enrolled and topline data expected in fourth quarter 2027

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other EyePoint, Inc. 8-K filings

Get the next EYPT 8-K as it lands

Follow EYPT for push alerts, or ask the research agent what this filing means.